Simulations Plus, Inc. (SLP)
Price:
19.18 USD
( - -0.33 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Privia Health Group, Inc.
VALUE SCORE:
8
2nd position
HealthEquity, Inc.
VALUE SCORE:
8
The best
Progyny, Inc.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
NEWS
3 Software Stocks to Watch as the Industry Gains Momentum
zacks.com
2025-12-09 09:36:05Steady digital transformation and strong adoption of AI bode well for Computer Software industry participants like SNPS, DSGX and SLP amid broader market volatility.
Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
businesswire.com
2025-12-09 07:55:00RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokinetic.
Why Shares of Simulations Plus Soared This Week
fool.com
2025-12-04 12:30:00The stock has taken a beating over the past few years, so expectations may have been low.
Simulations Plus: Buying On Long-Term Silico Drug-Development
seekingalpha.com
2025-12-02 21:41:59Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP's services help across discovery, development, and clinical operations. Software remains their main economic driver with higher margins. Services are growing faster and gradually increasing their share of total revenues but have lower margins.
Why Simulations Plus Stock Was Soaring Today
fool.com
2025-12-02 15:40:07Its full-year fiscal 2025 featured a double-digit revenue increase. As for the fourth quarter, its performance was mixed.
Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound
benzinga.com
2025-12-02 12:52:46Simulations Plus Inc. (NASDAQ: SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance.
Simulations Plus' Q4 Earnings & Sales Meet Estimates, Fall Y/Y
zacks.com
2025-12-02 10:11:11SLP posts softer fiscal Q4 2025 results but meets full-year goals as cloud, AI and integrated workflows shape its next growth phase.
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
seekingalpha.com
2025-12-01 20:13:24Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
businesswire.com
2025-12-01 16:05:00RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software rev.
First Look: Airbus drops, Crypto slides, Cyber Monday
gurufocus.com
2025-12-01 07:37:00Stock News Airbus shares sink on fresh A320 quality snag: Airbus (EADSY) fell after reports of an industrial quality issue affecting fuselage panels on dozens o
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm
prnewswire.com
2025-11-28 15:10:00NEWTOWN, Pa. , Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.
Simulations Plus (SLP) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com
2025-11-24 11:01:09Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
prnewswire.com
2025-11-20 10:00:00NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Analyzing The Descartes Systems Group (NASDAQ:DSGX) & Simulations Plus (NASDAQ:SLP)
defenseworld.net
2025-11-19 01:16:54Simulations Plus (NASDAQ: SLP - Get Free Report) and The Descartes Systems Group (NASDAQ: DSGX - Get Free Report) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Institutional and Insider Ownership
Campbell & CO Investment Adviser LLC Acquires Shares of 13,581 Simulations Plus, Inc. $SLP
defenseworld.net
2025-11-18 03:52:53Campbell and CO Investment Adviser LLC acquired a new stake in Simulations Plus, Inc. (NASDAQ: SLP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,581 shares of the technology company's stock, valued at approximately $237,000. Campbell and CO Investment Adviser LLC
Envestnet Asset Management Inc. Has $2.81 Million Stake in Simulations Plus, Inc. $SLP
defenseworld.net
2025-11-17 04:34:54Envestnet Asset Management Inc. increased its stake in shares of Simulations Plus, Inc. (NASDAQ: SLP) by 95.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,752 shares of the technology company's stock after buying an additional 78,466 shares
3 Software Stocks to Watch as the Industry Gains Momentum
zacks.com
2025-12-09 09:36:05Steady digital transformation and strong adoption of AI bode well for Computer Software industry participants like SNPS, DSGX and SLP amid broader market volatility.
Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
businesswire.com
2025-12-09 07:55:00RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokinetic.
Why Shares of Simulations Plus Soared This Week
fool.com
2025-12-04 12:30:00The stock has taken a beating over the past few years, so expectations may have been low.
Simulations Plus: Buying On Long-Term Silico Drug-Development
seekingalpha.com
2025-12-02 21:41:59Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP's services help across discovery, development, and clinical operations. Software remains their main economic driver with higher margins. Services are growing faster and gradually increasing their share of total revenues but have lower margins.
Why Simulations Plus Stock Was Soaring Today
fool.com
2025-12-02 15:40:07Its full-year fiscal 2025 featured a double-digit revenue increase. As for the fourth quarter, its performance was mixed.
Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound
benzinga.com
2025-12-02 12:52:46Simulations Plus Inc. (NASDAQ: SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance.
Simulations Plus' Q4 Earnings & Sales Meet Estimates, Fall Y/Y
zacks.com
2025-12-02 10:11:11SLP posts softer fiscal Q4 2025 results but meets full-year goals as cloud, AI and integrated workflows shape its next growth phase.
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
seekingalpha.com
2025-12-01 20:13:24Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
businesswire.com
2025-12-01 16:05:00RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software rev.
First Look: Airbus drops, Crypto slides, Cyber Monday
gurufocus.com
2025-12-01 07:37:00Stock News Airbus shares sink on fresh A320 quality snag: Airbus (EADSY) fell after reports of an industrial quality issue affecting fuselage panels on dozens o
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm
prnewswire.com
2025-11-28 15:10:00NEWTOWN, Pa. , Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.
Simulations Plus (SLP) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com
2025-11-24 11:01:09Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP
prnewswire.com
2025-11-20 10:00:00NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Analyzing The Descartes Systems Group (NASDAQ:DSGX) & Simulations Plus (NASDAQ:SLP)
defenseworld.net
2025-11-19 01:16:54Simulations Plus (NASDAQ: SLP - Get Free Report) and The Descartes Systems Group (NASDAQ: DSGX - Get Free Report) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Institutional and Insider Ownership
Campbell & CO Investment Adviser LLC Acquires Shares of 13,581 Simulations Plus, Inc. $SLP
defenseworld.net
2025-11-18 03:52:53Campbell and CO Investment Adviser LLC acquired a new stake in Simulations Plus, Inc. (NASDAQ: SLP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,581 shares of the technology company's stock, valued at approximately $237,000. Campbell and CO Investment Adviser LLC
Envestnet Asset Management Inc. Has $2.81 Million Stake in Simulations Plus, Inc. $SLP
defenseworld.net
2025-11-17 04:34:54Envestnet Asset Management Inc. increased its stake in shares of Simulations Plus, Inc. (NASDAQ: SLP) by 95.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,752 shares of the technology company's stock after buying an additional 78,466 shares